Medizinische Universitat Wien | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)	diabetic macular edema	Active, not recruiting	Not stated	2026-10-02		NCT06680817
Extension Study for the Port Delivery System With Ranibizumab (Portal)	Neovascular Age-Related Macular Degeneration	Recruiting	Phase 3	2026-09-28		NCT03683251
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 2 / Phase 3	2026-09-16		NCT04613596
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)	Neovascular Age-related Macular Degeneration (nAMD)	Active, not recruiting	Phase 3	2026-07-31		NCT04657289
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome	Recruiting	Phase 2 / Phase 3	2026-02-18		NCT04833894
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	Metastatic HER2-positive Breast Cancer	Recruiting	Phase 3	2026-02-10		NCT06435429